-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2023-503628-22-00
5
2020-07-16
Lupus Nephritis (LN)
-
2023-509089-39-00
5
2020-07-01
Non-Muscle Invasive Bladder Cancer
-
2022-501974-21-00
5
2020-04-01
Prevention of oral persistent infection caused by any of the human pap
-
2023-503500-87-00
11
2020-03-17
Muscle Invasive Bladder Cancer
-
2023-507886-25-00
4
2019-09-27
Previously untreated and symptomatic patients with histologically prov
-
2024-511641-18-00
4
2019-08-01
Diffuse Large B-cell Lymphoma ABC
-
2023-506733-30-00
4
2019-05-16
Multiple Myeloma relapsed and/or refractory
-
2024-513396-41-00
5
2019-05-15
PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR N
-
2023-509576-42-00
5
2019-02-21
Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB
-
2023-510015-19-00
5
2019-02-11
Patients with histologically or cytologically documented muscle-invasi
-
2023-505495-30-00
5
2019-02-01
Immunoglobulin A Nephropathy (IgAN)
-
2024-516844-25-01
4
2019-01-03
Patients with ras-mutated metastatIc colorectal cancer
-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2022-501966-23-00
5
2018-09-11
Resected High-Risk Stage II Melanoma
-
2024-512049-17-00
6
2018-09-05
Newly diagnosed MM patients >= 65 years old or ineligible for autologo
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-510434-83-00
6
2016-10-17
Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
-
2023-506524-82-00
5
2015-10-21
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirme
-
2024-512413-40-00
4
2013-03-08
Chronic myeloproliferative neoplasm
-
2023-503298-39-00
5
2024-06-13
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
-
2024-515152-20-00
4
2023-03-02
Stage III and high-risk stage II resected colon cancer patients.
-
2024-511708-18-00
4
2022-12-06
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung c